कंपनी का अवलोकन
Orthofix Medical Inc. operates as a comprehensive medical technology enterprise serving markets across the United States, Italy, the United Kingdom, France, Germany, Brazil, and various international regions. The corporation functions through two primary business segments: Global Spine and Global Limb Reconstruction, focusing on the development and distribution of advanced medical devices. This entity functions within the Healthcare sector, specifically targeting the Medical Devices industry, which implies a reliance on regulatory compliance and specialized manufacturing capabilities. The company's financial scale is defined by a market capitalization of $461.66M and an annual revenue of $822.31M, supported by a workforce of 1605 employees. These valuation and revenue figures indicate that Orthofix Medical Inc. maintains a mid-sized position in the market, reflecting its operational footprint without yet achieving the massive capitalization of dominant industry leaders, suggesting a company in a growth or stabilization phase rather than a mature monopoly status.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $822.31M, yet this generated a net income of $-92,192,000, while the EBITDA stood at $-6,147,000. The substantial disparity between the positive revenue of $822.31M and the negative net income of $-92.19M reveals a significant cost structure burden, where operating expenses likely exceed gross profits by a wide margin. Despite the negative net income, the company generated a free cash flow of $20.53M, which provides a critical layer of financial flexibility to fund operations or strategic initiatives despite accounting losses. Profitability analysis shows a gross margin of 68.8%, indicating efficient production and pricing power, contrasted sharply by an operating margin of -1.3% and a profit margin of -11.2%, which highlights severe overhead pressures or restructuring costs. The balance sheet holds $82.03M in cash against $203.85M in debt, resulting in a debt-to-equity ratio of 45.30, indicating a highly leveraged position where debt obligations significantly outweigh equity capitalization. However, the current ratio of 2.44 suggests robust short-term liquidity, as current assets are more than double current liabilities, ensuring the ability to meet immediate obligations. Furthermore, the return on equity of -19.3% and return on assets of -4.9% demonstrate that management effectiveness is currently challenged, as the company is destroying value for shareholders and failing to generate sufficient returns on the asset base employed.
मूल्यांकन आकलन
Valuation metrics present a mixed picture with a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed at 13.45. The absence of a trailing P/E and the presence of a forward P/E of 13.45 imply that the market is pricing in expected future earnings recovery, assuming profitability will return soon to justify the current valuation. The price-to-book ratio stands at 1.02, indicating that the market values the company at essentially par to its book value, suggesting no significant premium or discount relative to its tangible net assets. Alternative valuation multiples show a price-to-sales ratio of 0.56 and an EV/EBITDA of -94.92, which suggests the market is valuing the firm primarily on sales multiples rather than earnings power, typical for companies in turnaround situations or those with significant intangible assets. The stock has traded between a 52-week high of $17.00 and a 52-week low of $10.24, meaning the current price sits somewhere within this range but is notably below the recent peak. The beta value of 0.78 indicates that the stock's price volatility is lower than the broader market, suggesting it may act as a defensive position during market downturns relative to more volatile healthcare peers.
Growth & Income
The company achieved a revenue growth rate of 2.0% year-over-year, while the earnings growth rate is listed as N/A due to the negative earnings history. Since earnings are negative, there is no earnings growth to compare directly against revenue, but the modest 2.0% revenue increase implies stable but slow expansion in sales volume or pricing. As Orthofix Medical Inc. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, the company reinvests all available cash flow, including the $20.53M in free cash flow, into business operations, debt reduction, or growth initiatives rather than distributing income to shareholders. The overall growth and income profile is characterized by moderate revenue expansion and a complete lack of dividend income, reflecting a strategy focused on capital retention and operational turnaround rather than immediate shareholder returns.